Company Description
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.
Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
| Country | Israel |
| Founded | 2000 |
| IPO Date | Mar 13, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Allen Baharaff |
Contact Details
Address: 16 Abba Hillel Road Ramat Gan, 5250608 Israel | |
| Phone | 972 3 693 8448 |
| Website | galmedpharma.com |
Stock Details
| Ticker Symbol | GLMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595353 |
| CUSIP Number | M47238106 |
| ISIN Number | IL0011313900 |
| Employer ID | 98-1147233 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Allen Baharaff | Co-Founder, President, Chief Executive Officer and Chairman |
| Doron Cohen | Chief Financial Officer |
| Guy Nehemya | Chief Operating Officer and Data Protection Officer |
| Yohai Stenzler CPA | Chief Accounting Officer |
| Dr. Tali Gorfine | Medical Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2024 | EFFECT | Notice of Effectiveness |
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 21, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Oct 21, 2024 | 6-K | Report of foreign issuer |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Sep 25, 2024 | 6-K | Report of foreign issuer |
| Sep 20, 2024 | 6-K | Report of foreign issuer |
| Sep 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 19, 2024 | 6-K | Report of foreign issuer |